# Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia

> **NCT00868127** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 574 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Lapaquistat acetate
- **DRUG:** Lapaquistat acetate and additional lipid-lowering therapy

## Key facts

- **NCT ID:** NCT00868127
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 574 (ACTUAL)
- **Last updated:** 2012-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868127, "Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00868127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*